Literature DB >> 1708835

Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice.

R M Sharkey1, K S Weadock, A Natale, L Haywood, R Aninipot, R D Blumenthal, D M Goldenberg.   

Abstract

The potential for radioimmunotherapy as an adjuvant treatment for early disseminated colonic cancer was investigated in an experimental lung metastasis model. Nude mice receiving intravenous injection with a suspension of human colonic cancer cells (GW-39) developed multiple (10-100) tumor nodules throughout the lungs, and more than 50% of the animals died of extensive tumor involvement within 5-10 weeks. Groups of eight or nine animals bearing 7-day-old tumor transplants were treated with a single intravenous injection of radioiodinated agents: either 0.15 or 0.30 mCi of whole IgG of the NP-4 murine monoclonal antibody (MAb) against carcinoembryonic antigen (CEA) or 0.15 or 0.30 mCi of whole IgG of Immu-31, an anti-alpha-fetoprotein (anti-AFP) MAb. Treatment of animals with 0.15 or 0.30 mCi of 131I-labeled NP-4 IgG 7 days after injection of tumor cells resulted in survival for 23 weeks after tumor implantation in four of eight and seven of nine animals, respectively. Microscopic examination revealed that over 90% of the lung tumor colonies had no evidence of surviving cells. Animals treated with 0.30 mCi of anti-AFP, an irrelevant MAb, survived 4 weeks longer than controls. Toxicity was evident in four of the 17 animals given 0.30 mCi of NP-4 IgG (specific) or anti-AFP IgG (irrelevant) MAb. These animals died within 1-3 weeks after radioantibody injection, suggesting that death was related to the radiation dose. None of the animals given 0.15 mCi of 131I-MAb died within this period.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708835     DOI: 10.1093/jnci/83.9.627

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

Review 1.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

2.  Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.

Authors:  Franz Buchegger; Oliver W Press
Journal:  EJNMMI Res       Date:  2011-06-20       Impact factor: 3.138

3.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 4.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

5.  CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

Authors:  Serengulam V Govindan; Thomas M Cardillo; Sung-Ju Moon; Hans J Hansen; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

6.  Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.

Authors:  Seigo Kinuya; Kunihiko Yokoyama; Kiyoshi Koshida; Hirofumi Mori; Kazuhiro Shiba; Naoto Watanabe; Noriyuki Shuke; Jingming Bai; Takatoshi Michigishi; Norihisa Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-28       Impact factor: 9.236

Review 7.  Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

8.  Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer.

Authors:  Seigo Kinuya; Kunihiko Yokoyama; Mishiroku Izumo; Takami Sorita; Takashi Obata; Hirofumi Mori; Kazuhiro Shiba; Naoto Watanabe; Noriyuki Shuke; Takatoshi Michigishi; Norihisa Tonami
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

9.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors:  David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal:  Update Cancer Ther       Date:  2007-03

10.  Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.

Authors:  Lore Santoro; Samir Boutaleb; Véronique Garambois; Caroline Bascoul-Mollevi; Vincent Boudousq; Pierre-Olivier Kotzki; Monique Pèlegrin; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.